Development of antithrombotic nanoconjugate blocking integrin α2β1-collagen interactions

Area of Science:

• Biomaterials Science
• Nanotechnology
• Pharmacology

Background:

• The peptide LWWNSYY inhibits integrin α2β1-collagen interaction, crucial for thrombus formation.
• High hydrophobicity of LWWNSYY leads to clustering in physiological environments, limiting its practical application.
• Poly(glycidyl methacrylate) nanoparticles (PGMA NPs) offer a platform to improve peptide dispersibility.

Purpose of the Study:

• To design and characterize an antithrombotic nanoconjugate using LWWNSYY peptide immobilized on PGMA NPs.
• To evaluate the improved dispersibility, collagen binding affinity, and antithrombotic efficacy of the LWWNSYY-PGMA nanoparticles (L-PGMA NPs).

Main Methods:

• Immobilization of LWWNSYY peptide onto PGMA NPs to create L-PGMA NPs.
• Assessment of collagen receptor binding affinity using dissociation constant (Kd).
• In vitro evaluation of platelet adhesion inhibition (IC50) and in vivo assessment of thrombus formation inhibition.

Main Results:

• L-PGMA NPs demonstrated improved dispersibility of the LWWNSYY peptide.
• Binding to collagen receptors was observed with a Kd of 3.45 ± 1.06 μM.
• In vitro platelet adhesion inhibition showed a reduced IC50 of 1.83 ± 0.29 μg/mL, and in vivo studies confirmed a 50% reduction in thrombus weight.

Conclusions:

• L-PGMA NPs represent a promising antithrombotic nanomedicine with enhanced dispersibility and targeted delivery.
• The nanoconjugate effectively inhibits collagen-mediated platelet adhesion and thrombus formation.
• This approach offers a potential strategy for treating thrombotic diseases by targeting collagen exposed on diseased blood vessel walls.